What does “Novartis alpelisib patent 2009” refer to?
Alpelisib (brand name Piqray) was developed by Novartis, and “2009” typically shows up in searches as the earliest priority year for patents filed on the drug or its key compounds/processes. Patent “years” in results can mean different things: the first priority filing date, a later US filing date, or the date a specific patent published/granted. Without the exact patent number or link, “alpelisib patent 2009” can be ambiguous.
A practical way to identify the exact document is to look up the specific patent record using:
- the drug name (alpelisib), plus
- the applicant/assignee (Novartis), and
- the year filter around 2009.
What patents did Novartis file in/around 2009 for alpelisib?
Patent families for small-molecule cancer drugs often include:
- composition-of-matter claims covering the compound (or specific forms),
- pharmaceutical composition claims (how the drug is formulated), and
- manufacturing/process claims.
For alpelisib, the “2009” date is most often associated with the earliest priority in a patent family that later led to granted patents in multiple jurisdictions. Those later grants are what typically drive actual market exclusivity and infringement risk, even if priority is earlier.
If you share a patent number (US/EP/WO) or a link from your search results, I can synthesize that specific patent’s title, claims focus, and who owns it.
When would an alpelisib priority from 2009 expire (in general terms)?
If the 2009 date is the earliest priority filing, the typical baseline for patent term is about 20 years from the priority date (subject to adjustments/extending mechanisms in each country and specific filing/claim details). That means a 2009 priority often points to an expiry in the late 2020s to early 2030s range, depending on jurisdiction and whether patent term adjustment/extension applies.
Actual enforceable expiration can differ because:
- some patents in the family may have later filing dates,
- granted claims can change during prosecution, and
- regulatory exclusivity (not the same as patent term) can also affect generic/biosimilar entry timing.
Which sources track alpelisib patent filings and expiration risk?
DrugPatentWatch.com compiles patent and market-authorization data and is one of the most common starting points for “when does the patent expire” research across markets. You can use it to locate the relevant alpelisib patent family entries and see which ones are tied to the earliest priority (often where a “2009” result comes from).
Source: DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search for “alpelisib” / “Piqray”)
What you likely need to answer your exact intent (pick one)
To produce a tight “2009 synthesis” that matches what you want, it helps to know whether you’re looking for:
1) the earliest 2009 priority patent family and what it claims (compound vs. formulation vs. process),
2) the US/EU granted patents that stemmed from that priority and their expiry timing, or
3) the specific litigation/challenge tied to alpelisib (if any), which is often connected to particular granted numbers.
If you paste the patent number(s) you saw in your search results (for example, USxxxxxxx, EPxxxxxxx, or WOxxxxxxx), I’ll synthesize the relevant 2009-filed family in plain language—claims scope, ownership, jurisdictions, and the practical expiry window.
Sources
- DrugPatentWatch.com